We are a clinical-stage biopharmaceutical company committed to developing innovative drugs. Established in 2020 and located in Shanghai and Changshu, Suzhou, China, we primarily focus on in-house discovery and development of biopharmaceuticals targeting on allergic and autoimmune diseases. Driven by our proprietary technology platforms and strong R&D capabilities, we have developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases.
LongBio Pharma aims to bring our drugs to both domestic and international markets with our partners, especially to bring patients with more affordable and high-quality bio-medicines.
Our High-affinity Antibody Discovery Platform, on which we have developed LP-003, produces antibodies with significantly improved affinities that surpass traditional methods. With a proven track record, our High-affinity Antibody Discovery Platform has already developed several picomolar blocking monoclonal antibodies, including our LP-003.
We have established a novel Bi-functional Antibody Development Platform leveraging our proprietary antibody discovery and protein engineering technologies. This platform focuses on the development of differentiated bi-functional antibody biologics, with a view to addressing the limited therapeutic efficacy of single-target drugs, as well as the heightened costs, long duration and heavy patient burden associated with developing drugs targeting multiple pathways.
Our bi-functional antibody development strategy offers structural flexibility, broad applicability, and high druggability, extending beyond traditional antibody formats to include nanobodies, antibody fragments, receptors, regulatory proteins, and engineered Fc. This platform can be widely applied to generate various bi-functional antibodies, which will help us implement new treatment strategies in the fields of allergic diseases and autoimmunity.
Based on this platform，we have developed LP-005, LP-00A, LP-00C and LP-00D.
Our High-affinity Antibody Discovery Platform, on which we have developed LP-003, produces antibodies with significantly improved affinities that surpass traditional methods. With a proven track record, our High-affinity Antibody Discovery Platform has already developed several picomolar blocking monoclonal antibodies, including our LP-003.
We have established a novel Bi-functional Antibody Development Platform leveraging our proprietary antibody discovery and protein engineering technologies. This platform focuses on the development of differentiated bi-functional antibody biologics, with a view to addressing the limited therapeutic efficacy of single-target drugs, as well as the heightened costs, long duration and heavy patient burden associated with developing drugs targeting multiple pathways.
Our bi-functional antibody development strategy offers structural flexibility, broad applicability, and high druggability, extending beyond traditional antibody formats to include nanobodies, antibody fragments, receptors, regulatory proteins, and engineered Fc. This platform can be widely applied to generate various bi-functional antibodies, which will help us implement new treatment strategies in the fields of allergic diseases and autoimmunity.
Based on this platform，we have developed LP-005, LP-00A, LP-00C and LP-00D.
longBio
News